JP2025506001A - 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 - Google Patents

225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Download PDF

Info

Publication number
JP2025506001A
JP2025506001A JP2024546261A JP2024546261A JP2025506001A JP 2025506001 A JP2025506001 A JP 2025506001A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A JP2025506001 A JP 2025506001A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
acid
mbq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506001A5 (cg-RX-API-DMAC7.html
Inventor
カスタルディ,エレナ
ザヒ,イリエス
カヴァイアー,ロベルト フォルメント
マイネロ,ヴァレンティナ
エフ マリアニ,マウリツィオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2025506001A publication Critical patent/JP2025506001A/ja
Publication of JP2025506001A5 publication Critical patent/JP2025506001A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024546261A 2022-02-09 2023-02-09 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Pending JP2025506001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308211P 2022-02-09 2022-02-09
US63/308,211 2022-02-09
PCT/IB2023/051159 WO2023152671A1 (en) 2022-02-09 2023-02-09 Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Publications (2)

Publication Number Publication Date
JP2025506001A true JP2025506001A (ja) 2025-03-05
JP2025506001A5 JP2025506001A5 (cg-RX-API-DMAC7.html) 2026-02-06

Family

ID=85328574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546261A Pending JP2025506001A (ja) 2022-02-09 2023-02-09 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物

Country Status (5)

Country Link
US (1) US20250161502A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475900A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506001A (cg-RX-API-DMAC7.html)
CN (1) CN118647415A (cg-RX-API-DMAC7.html)
WO (1) WO2023152671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025058000A1 (cg-RX-API-DMAC7.html) 2023-09-13 2025-03-20
WO2025218879A1 (en) * 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
WO2025255396A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
WO2026089608A2 (en) 2024-10-21 2026-04-30 Erasmus University Medical Center Rotterdam Radiopharmaceuticals
WO2026120497A1 (en) * 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606012A2 (en) * 2003-03-25 2005-12-21 Sloan-Kettering Institute For Cancer Research Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy
KR20250057132A (ko) 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CA3185968A1 (en) * 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4274835A1 (en) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof

Also Published As

Publication number Publication date
WO2023152671A1 (en) 2023-08-17
CN118647415A (zh) 2024-09-13
US20250161502A1 (en) 2025-05-22
EP4475900A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
Li et al. Functionally versatile and highly stable chelator for 111In and 177Lu: Proof-of-principle prostate-specific membrane antigen targeting
CN108290924B (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
AU2014396468B2 (en) Modified cyclopentapeptides and uses thereof
US20250161502A1 (en) Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
JP2020528461A (ja) デュアルモードの放射性トレーサーおよび療法剤
JP7673056B2 (ja) Grprアンタゴニストを放射標識するための方法及びそれらのキット
JP7762648B2 (ja) 安定した濃縮放射性医薬組成物
SA96160495B1 (ar) استخدام ببتيدات سوماتوستاتين somatostatin peptides معقدة عديدة للتصوير الحيوي للأورام وانتشار الورم الموطب لمستقبل السوماتوستاتين somatostatin receptor
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
JP7646637B2 (ja) 画像化及び治療用組成物
Läppchen et al. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
US7122622B2 (en) Peptide compounds having improved binding affinity to somatostatin receptors
JP2023506297A (ja) 癌のイメージングおよび治療のための修飾されたgrprアンタゴニストペプチド
JP6410339B2 (ja) 放射性核種標識オクトレオチド誘導体
EP4631959A2 (en) Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
US20240254085A1 (en) Chelators for radiometals and methods of making and using same
CN113195005A (zh) 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
US12486294B2 (en) Radioisotope labeled compound for imaging or treatment of prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260129